Equities

Balaxi Pharmaceuticals Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BALAXI:NSI

Balaxi Pharmaceuticals Ltd

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (INR)22.87
  • Today's Change-0.11 / -0.48%
  • Shares traded60.82k
  • 1 Year change-67.14%
  • Beta1.0659
Data delayed at least 15 minutes, as of Feb 06 2026 09:59 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Balaxi Pharmaceuticals Limited is an India-based company. The Company operates as an intellectual property right (IPR)-based pharmaceutical company. The Company primarily operates in frontier markets across the Americas, Africa and the Caribbean islands. The Company is focusing on frontier markets, with a growing portfolio of drugs across multiple therapeutic segments. It is engaged in International Wholesale Distribution of Pharmaceuticals. The Company’s products include Anti-biotic, Analgesic, Medical Device, Vitamins, Anti-Malaria, Erectile Dysfunction, Hypertension, Anti-Asthma, Steroid, Anti-Helminthic, Anti-Ulcer, Hygiene, Anticholinergic, Dietary Supplement, Diuretic, Hormone, Anti-Emetic, Bronchodilator, Local Anesthetic, Anemia, Anti-Diarrhea, Antihistamine, Hypotension, Antacid, Anti-Tuberculosis, Insect Repellents, and Laxative. Its Boadent brand includes anticavity dental toothpaste. Its subsidiaries are Balaxi Global DMCC, Dubai and Balaxi healthcare Ecuador.

  • Revenue in INR (TTM)2.76bn
  • Net income in INR94.42m
  • Incorporated1942
  • Employees48.00
  • Location
    Balaxi Pharmaceuticals LtdPlot No: 409, 3rd Floor,Maps TowersJubilee Hills,Road No:81, HyderabadHYDERABAD 500096IndiaIND
  • Phone+91 4 023555300
  • Fax+91 4 023558085
  • Websitehttps://balaxipharma.in/
More ▼

Institutional shareholders

8.29%Per cent of shares held by top holders
HolderShares% Held
Elara Capital Plc (Investment Management)as of 30 Sep 20244.58m8.29%
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.